Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor VH BCa at radical cystectomy. We aimed to create a personalized follow-up scheme that dynamically weighs OCM versus the risk of recurrence for VH BCa, and to compare it with a similar one for pUC.